NasdaqGS:NTRABiotechs
How Investors May Respond To Natera (NTRA) MRD Breakthrough, AI Push And 2025 Revenue Outlook
Natera, Inc. recently reported a peer-reviewed validation in npj Precision Oncology for its Latitude tissue-free MRD assay in colorectal cancer, showing high sensitivity, high specificity and strong prognostic and predictive value, while also issuing preliminary 2025 revenue guidance of about US$2.30 billion, up roughly 35% year over year.
Together with ongoing AI-enabled advances in its Signatera franchise and a new collaboration with NVIDIA, the data-rich Latitude study strengthens...